# Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101

> **NCT07168226** · PHASE2 · NOT_YET_RECRUITING · sponsor: **MetaFines** · enrollment: 135 (estimated)

## Conditions studied

- Cachexia; Cancer

## Interventions

- **DRUG:** Active Comparator
- **DRUG:** ASCA101 24.32mg/kg
- **DRUG:** ASCA101 32.43mg/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07168226
- **Lead sponsor:** MetaFines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2026-03-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07168226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07168226, "Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07168226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*